Adrenal medulla is involved in the aldosterone secretagogue effect of substance P
Abstract
Substance P (SP) increased aldosterone secretion of rat adrenal slices, but not of isolated zona glomerulosa cells, and this effect was annulled by two specific antagonist of SP (SP-A). Both tissue preparations displayed an aldosterone secretory response to isoprenaline (IP) that was blocked by l-alprenolol (AL). AL reversed the aldosterone response of adrenal slices to IP, SP, or IP plus SP, whereas SP-A only suppressed that to SP. Quarters of adrenocortical autotransplants, which are completely deprived of chromaffin cells, showed an aldosterone response to IP, but not to SP. These findings suggest that the mechanism underlying the aldosterone secretagogue action of SP probably involves the stimulation of catecholamine release by adrenal medulla chromaffin cells.
References
Inhibition of CRH-41 release by substance P, but not substance K, from the rat hypothalamus in vitro
Substance P-like immunoreactivity in adrenal chromaffin cells and intra-adrenal nerve fibers of rats
Citations
Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis
Related Concepts
Related Feeds
Allogenic & Autologous Therapies
Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.